Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

EOC Pharma Completed Series B Financing From Leading Global Investors

EOC Pharma Group
Posted on: 07 Nov 17

EOC Pharma Group (EOC), a leading oncology-focused development and commercialization company in China, today announced that it has completed a $32 million Series B financing led by Taikang Investment through Shandong State-owned Taikang Industry Development Fund (Taikang). Sequoia China, EOC’s Series A lead investor, and H&Q Asia Pacific, also participated in the round.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171107005281/en/

Dr. Xiaoming Zou, EOC Pharma's Founder and CEO

EOC is dedicated to rapidly developing and commercializing innovative global oncology products in China. The funds will be used to advance the development of EOC’s mid- and late-stage clinical pipeline, and to in-license additional late-stage oncology assets to bring new treatment options to patients in China.

“Investment from these top funds underscores the confidence in our strategy to advance differentiated, globally developed oncology products that can transform patients’ lives,” commented Dr. Xiaoming Zou, EOC Pharma’s Founder and CEO. “Our team’s unique track record for strategic partnering and commercialization in China, along with our dedicated manufacturing and local development capabilities, position EOC to successfully leverage the improved clinical and regulatory environment and rapidly growing healthcare market in China.”

EOC Pharma has licensed clinical-stage, potentially transformative product candidates from leading global pharmaceutical and biotech companies. The Company currently has a broad portfolio of drug candidates, including two innovative small molecule products expected to enter Phase 3 registration studies in China in 2018 for the treatment of breast cancer and gastric cancer, respectively. Its pipeline also includes innovative biologics being developed for indications in immuno-oncology and tumor metastasis.

Taikang committed its financial resources to EOC to support the further development of its powerful platform designed to bring globally developed innovative drugs to patients in China who currently have limited treatment options.

About EOC

EOC is a fast-growing, Shanghai-based biopharmaceutical company that is focused on the in-licensing of innovative global oncology products, and developing, manufacturing and commercializing them for the China market. The Company is building a fully integrated manufacturing, development and commercialization platform, and has a pipeline of six novel products from global biopharmaceutical partners that are potentially first- and best-in-class. EOC is a spin-off of the oncology division of Eddingpharm, a leading specialty pharmaceutical company in China that is dedicated to in-licensing, marketing and commercializing branded drugs from global pharmaceutical companies.

About Shandong State-owned Taikang Industry Development Fund

Shandong State-owned Taikang Industry Development Fund is the first private equity fund raised and managed by Taikang Investment and its partner Juneng Capital. The fund size is RMB 5 billion, and focused on healthcare, consumer industry and SOE reform investment. Taikang Investment is the PE platform of Taikang Asset Management. With over RMB 1,100 billion AUM, Taikang Asset Management is one of the largest institutional investors in China.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005281/en/

Business Wire
www.businesswire.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.